PTN Palatin Technologies, Inc.

0.910.00 (-0.02%)
Close: August 22, 2019

0.920.01 (+1.12%)
After hours

Quote

Previous Close
$0.91
Day Range
$0.90-$0.94
52 Week Range
$0.59-$1.78
Volume
747,859
Avg Volume
1,444,627
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$196.11M
Enterprise Value (EV)
$164.44M
PE Ratio
-
EV/EBITDA
6.33
Price/Sales
-
Price/Book
7.27
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
$25.98M
EPS, ttm
-$0.02
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
9/11/2019 (19 days)
Debt to Equity
23%
Debt
$6.32M
Cash
$38.00M
Net Debt
-

Performance

Beta
1.02
200 Day Moving Avg
$0.98
50 Day Moving Avg
$1.02
52 Week Change
-4.86%
YTD Change
18.07%
1 Month Change
-6.60%
3 Month Change
-40.91%
6 Month Change
7.81%
1 Year Change
-4.86%
2 Year Change
184.16%
5 Year Change
8.70%

Share Count

Shares Outstanding
215.6M
Float
200.9M
Restricted Shares
14.6M
Restricted Shares, %
6.78%

Palatin Technologies, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Carl Spana

Website: http://www.palatin.com

Description: Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Employees: 19